2-, 5-, and 6-halo-3-(2(S)-azetidinylmethoxy)pyridines:: Synthesis, affinity for nicotinic acetylcholine receptors, and molecular modeling

被引:121
作者
Koren, AO
Horti, AG
Mukhin, AG
Gündisch, D
Kimes, AS
Dannals, RF
London, ED
机构
[1] NIDA, Intramural Res Program, Brain Imaging Ctr, Baltimore, MD 21224 USA
[2] Johns Hopkins Med Inst, Dept Radiol, Div Nucl Med, Baltimore, MD 21287 USA
关键词
D O I
10.1021/jm980170a
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
3-(2(S)-Azetidinylmethoxy)pyridine (A-85380) has been identified recently as a ligand with high affinity for nicotinic acetylcholine receptors (nAChRs). Here we report the synthesis and in vitro nAChR binding of a series of 10 pyridine-modified analogues of A-85380; The novel compounds feature a halogen substituent at position 2, 5, or 6 of the 3-pyridyl fragment. Those with the substituents at position 5 or 6, as well as the 2-fluoro analogue, possess subnanomolar affinity for nAChRs in membranes from rat brain. For these ligands, K-i values range from 11 to 210 pM, as measured by competition with (+/-)-[H-3]epibatidine. In contrast, 2-chloro, 2-bromo, and 2-iodo analogues exhibit substantially lower affinity. AM1 quantum chemical calculations demonstrate that the bulky substituents at position 2 cause notable changes in the molecular geometry. The high-affinity members of the series and (+)-epibatidine display a tight fit superposition of low-energy stable conformers. The new ligands with high affinity for nAChRs may be of interest as pharmacological probes, potential medications, and candidates for developing radiohalogenated tracers to study nAChRs.
引用
收藏
页码:3690 / 3698
页数:9
相关论文
共 45 条
[31]   Nicotinic system involvement in Alzheimer's and Parkinson's diseases - Implications for therapeutics [J].
Newhouse, PA ;
Potter, A ;
Levin, ED .
DRUGS & AGING, 1997, 11 (03) :206-228
[32]   KINETIC-ANALYSIS OF REGIONAL (S)(-)C-11-NICOTINE BINDING IN NORMAL AND ALZHEIMER BRAINS - IN-VIVO ASSESSMENT USING POSITRON EMISSION TOMOGRAPHY [J].
NORDBERG, A ;
LUNDQVIST, H ;
HARTVIG, P ;
LILJA, A ;
LANGSTROM, B .
ALZHEIMER DISEASE & ASSOCIATED DISORDERS, 1995, 9 (01) :21-27
[33]   PET STUDIES OF THE UPTAKE OF (S)-[C-11]NICOTINE AND (R)-[C-11]NICOTINE IN THE HUMAN BRAIN - DIFFICULTIES IN VISUALIZING SPECIFIC RECEPTOR-BINDING IN-VIVO [J].
NYBACK, H ;
HALLDIN, C ;
AHLIN, A ;
CURVALL, M ;
ERIKSSON, L .
PSYCHOPHARMACOLOGY, 1994, 115 (1-2) :31-36
[34]  
Patt J. T., 1995, Journal of Labelled Compounds and Radiopharmaceuticals, V37, P355
[35]  
Pauly J. R., 1996, Society for Neuroscience Abstracts, V22, P1264
[36]  
Saji H, 1997, CHEM PHARM BULL, V45, P284
[37]  
SalinPascual RJ, 1996, J CLIN PSYCHIAT, V57, P387
[38]   Nicotine for the treatment of Tourette's syndrome [J].
Sanberg, PR ;
Silver, AA ;
Shytle, RD ;
Philipp, MK ;
Cahill, DW ;
Fogelson, HM ;
McConville, BJ .
PHARMACOLOGY & THERAPEUTICS, 1997, 74 (01) :21-25
[39]   Preparation of 5-hydroxy-2-iodopyridine: A refutation of earlier reports [J].
Sheldrake, PW ;
Powling, LC ;
Slaich, PK .
JOURNAL OF ORGANIC CHEMISTRY, 1997, 62 (09) :3008-3009
[40]   THE ENSEMBLE APPROACH TO DISTANCE GEOMETRY - APPLICATION TO THE NICOTINIC PHARMACOPHORE [J].
SHERIDAN, RP ;
NILAKANTAN, R ;
DIXON, JS ;
VENKATARAGHAVAN, R .
JOURNAL OF MEDICINAL CHEMISTRY, 1986, 29 (06) :899-906